- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Patent holdings for IPC class C07D 207/16
Total number of patents in this class: 1187
10-year publication summary
|
87
|
76
|
85
|
103
|
85
|
60
|
67
|
56
|
71
|
8
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7881 |
27 |
| Bristol-myers Squibb Company | 4809 |
17 |
| Givaudan SA | 1929 |
16 |
| Epics Therapeutics | 22 |
15 |
| Novartis AG | 10481 |
14 |
| Hoffmann-La Roche Inc. | 3603 |
14 |
| Omeros Corporation | 310 |
14 |
| ThermoLife International, LLC | 130 |
13 |
| Life Technologies Corporation | 3370 |
12 |
| President and Fellows of Harvard College | 6053 |
12 |
| Aichi Steel Corporation | 391 |
11 |
| Tokushima University | 233 |
11 |
| Xwpharma Ltd. | 60 |
11 |
| Biogen MA Inc. | 923 |
10 |
| Cytokinetics, Inc. | 267 |
10 |
| Pfizer Inc. | 3376 |
9 |
| The Regents of the University of California | 20366 |
8 |
| Amgen Inc. | 4290 |
8 |
| Abbvie Inc. | 1823 |
8 |
| Enanta Pharmaceuticals, Inc. | 431 |
8 |
| Other owners | 939 |